Bluefish prepares for additional capital raising

Bluefish Pharmaceuticals, a Swedish generic pharmaceutical company, has commenced preparations to secure additional financing to further accelerate the pace of implementation of the Company’s expansion plan

The purpose of the new issue now being planned for is to further increase the pace of implementation of the Company’s expansion plan. This plan comprises both geographical expansion by establishing own presence in additional countries in Europe and a broadening of the product portfolio.

Nordea Bank has been appointed sole financial adviser with respect to the forthcoming capital raising and the subsequent Initial Public Offering being planned for. The intention is to complete the capital raising within the next few months and to prepare for an Initial Public Offering in 2008.

For further information:
Bluefish Pharmaceuticals
Karl Karlsson, President and CEO, tel +46 8 679 50 70
Susanna Urdmark, Executive VP, Global Product Strategy, tel +46 8 679 50 70

Nordea Bank
Thomas Westin, Executive Director, Nordea Corporate Finance, tel +46 8 534 915 98

Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops, manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly‐owned subsidiary in Chennai, India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.